Imricor Medical Systems Beheer

Beheer criteriumcontroles 3/4

De CEO Imricor Medical Systems is Steve Wedan, benoemd in May2006, heeft een ambtstermijn van 18.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 464.90K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.88% van de aandelen van het bedrijf, ter waarde A$ 3.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.3 jaar en 5.5 jaar.

Belangrijke informatie

Steve Wedan

Algemeen directeur

US$464.9k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	18.5yrs
Eigendom CEO	1.9%
Management gemiddelde ambtstermijn	6.3yrs
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Jan 24

What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?

Dec 02

What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition

Aug 18

Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)

Jun 25

Analyse CEO-vergoeding

Hoe is Steve Wedan's beloning veranderd ten opzichte van Imricor Medical Systems's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$465k	US$465k	-US$23m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$465k	US$465k	-US$17m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$20m
Dec 31 2021	US$577k	US$464k	-US$20m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$565k	US$452k	-US$12m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$349k	US$349k	-US$13m

Compensatie versus markt: De totale vergoeding ($USD 464.90K ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 303.52K ).

Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Steve Wedan (55 yo)

18.5yrs

Tenure

US$464,900

Compensatie

Mr. Steven Wedan, also known as Steve, has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has me...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Wedan	President	18.5yrs	US$464.90k	1.88% A$ 3.8m
Jonathon Gut	CFO & VP of Finance	2.3yrs	US$259.38k	geen gegevens
Gregg Stenzel	Chief Operating Officer	17.8yrs	US$315.00k	geen gegevens
Greg Englehardt	Vice President of Global Sales	6.8yrs	geen gegevens	geen gegevens
Nick Twohy	Vice President of Marketing & Business Development	5.8yrs	geen gegevens	geen gegevens
Kobe Lizheng	Company Secretary & Local Agent	5.6yrs	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van IMR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Wedan	President	18.5yrs	US$464.90k	1.88% A$ 3.8m
Anita Messal	Independent Non-Executive Director	3.7yrs	US$75.00k	0.13% A$ 261.3k
Peter McGregor	Independent Non-Executive Director	5.5yrs	US$80.00k	0.32% A$ 646.1k
Mark Tibbles	Independent Deputy Chairman & Lead Independent Director	10.2yrs	US$80.00k	2.31% A$ 4.6m
Jeffrey Leighton	Non-Independent Non-Executive Director	less than a year	geen gegevens	0.091% A$ 181.9k

5.5yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMR wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Imricor Medical Systems Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Insufficient new directors

Key Executive recently bought AU$195k worth of stock

President recently bought AU$76k worth of stock

Recent updates

Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Insufficient new directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022)

Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million.

First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)

New major risk - Revenue and earnings growth

New major risk - Share price stability

Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding

Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023

Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding

Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Key Executive recently bought AU$195k worth of stock

Full year 2022 earnings: Revenues miss analyst expectations

Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023

Imricor Medical Systems, Inc. Receives IDE Approval from US FDA

Forecast to breakeven in 2025

Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial

Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial

Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding

First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021)

Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022

Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022

Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely

Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe

Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022

Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 57%

Imricor Medical Systems, Inc. Announces Executive Changes

Consensus forecasts updated

Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration

First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020)

No longer forecast to breakeven

Consensus forecasts updated

We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely

Non-Executive Director has left the company

Imricor Medical Systems, Inc. Announces Board Changes

When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day low: AU$2.16

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO

Imricor Signs Supply and Sales Agreement with Osypka

What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?

Imricor Medical Systems, Inc. Signs New Purchase Agreement

New 90-day high: AU$2.78

Imricor Medical Systems, Inc. (ASX:IMR) signed an agreement to acquire Schleswig-Holstein University Medical Centre in Germany.

Imricor Medical Systems, Inc. to Commence Clinical Procedures After Receiving Ethics Committee Approval to Use Isuite Software

Imricor Awards National Institutes of Health Contract

Imricor Medical Systems, Inc. Signs Purchase Agreement with MUMC